Elevated concentrations of plasma α-melanocyte stimulating hormone are associated with reduced disease progression in HIV-infected patients

Journal of Laboratory and Clinical Medicine

Volumn 133, Issue 3, 1999, Pages 309-315

  Airaghi, Lorena ^a,b,c   Capra, Riccardo ^a,b,c   Pravettoni, Grazia ^a,b,c   Maggiolo, Franco ^a,b,c   Suter, Fredy ^a,b,c   Lipton, James M ^a,b,c   Catania, Anna ^a,b,c  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b BUSTO ARSIZIO HOSPITAL   (Italy)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERMEDIN; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN IMMUNODEFICIENCY VIRUS; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; PATHOGENESIS; T LYMPHOCYTE; TUMOR NECROSIS FACTOR RECEPTOR; VIRUS INFECTION;

EID: 0033104691     PISSN: 00222143     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-2143(99)90087-2     Document Type: Article

References (26)

1. 1. Catania A, Lipton JM. α-Melanocyte stimulating hormone in the modulation of host reactions. Endocr Rev 1993;14:564-76.
2. 2. Lipton JM, Catania A. Anti-inflammatory actions of the neuroimmunomodulalor α-MSH, Immunol Today 1997;18:140-5.
3. 3 Lipton JM, Ceriani G, Macaluso D, et al. Antiinflammatory effects of the neuropeptide α-MSH in acute, chronic, and systemic inflammation. Ann NY Acad Sci 1994;741:137-48.
4. 4. Airaghi L, Lettino M, Manfredi MG, Lipton JM, Catania A. Endogenous cytokine antagonists during myocardial ischemia and thrombolytic therapy. Am Heart J 1995;130:204-11.
5. 5. Catania A, Gerloni V, Procaccia S, et al. The anticytokine neuropeptide α-melanocyte-stimulating hormone in synovial fluid of patients with rheumatic diseases: comparisons with other anticytokine molecules, Neuroimmunomodulation 1994;1:321-8.
6. 6. Catania A, Airaghi L, Garofalo L, Cutuli M, Lipton JM. The neuropeptide α-MSH in AIDS and other conditions in humans. Ann NY Acad Sci 1998;840:848-56.
7. 7. Poli G, Fauci AS. Cytokine modulation of HIV expression. Semin Immunol 1993;5:165-73.
8. 8. Barcellini W, La Maestra L, Clerici G, Lipton JM, Catania A. Inhibitory influences of a-MSH peptides on HIV-1 expression in monocytic cells. Twelfth World AIDS Conference, Geneva, Switzerland, June 28-July 3, 1998.
9. 9. Catania A, Airaghi L, Manfredi MG, et al. Proopiomelanocortin-derived peptides and cytokines: relations in patients with acquired immunodeficiency syndrome. Clin Immunol Immunopathol 1993;66:73-9.
10. 10. Catania A, Manfredi MG, Airaghi L, et al. Plasma concentrations of cytokine antagonists in patients with HIV infection. Neuroimmunomodulation 1994;1:42-9.
11. 11. Centers for Disease Control. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR Morb Mortal Wkly Rep 1987;36:1S-15.
12. 12. Centers for Disease Control. 1993 Revised CDC HIV classification system and expanded AIDS surveillance definition for adolescents and adults. MMWR Morb Mortal Wkly Rep 1992;41(RR-17):1-19.
13. 13. Aiuti F, Bassetti D, Carosi CP, et al. Linee guida per la terapia antiretroviralc dell'infezione da HIV. Ministero della Sanità, Istituto Poligrafico e Zecca dello Stato, Roma, 1995.
14. 14. USPHS/IDSA Prevention of Opportunistic Infection Working Group. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: disease-specific recommendations. Clin Infect Dis 1995;21:32S-43.
15. 15. Catania A, Garofalo L, Cutuli M, Gringeri A, Santagostino E, Lipton JM. Melanocortin peptides inhibit production of proinflammatory cytokines in whole blood samples of patients infected with HIV. Peptides 1998;19:1099-104.
16. 16. Rajora N, Ceriani G, Catania A, et al. α-MSH production, receptors and influence on neopterin in a human monocyte/macrophage cell line. J Leukocyte Biol 1996;59:248-53.
17. 17. Star RA, Rajora N, Huang J, Chavez R, et al. Evidence of autocrine modulation of macrophage nitric oxide synthase by α-MSH. Proc Natl Acad Sci USA 1995;92:8016-20.
18. 18. Poli G, Kinter A, Justement JS, et al. Tumor necrosis factor a functions in an autocrine manner in the induction of human immunodeficiency virus expression. Proc Natl Acad Sci USA 1990;87:782-5.
19. 19. Lipton SA. Similarity of neuronal cell injury and death in AIDS dementia and focal cerebral ischemia: potential treatment with NMDA open-channel blockers and nitric oxide-related species. Brain Pathol 1996;6:507-17.
20. 20. Yeung MC, Pulliam L, Lau AS. The HIV envelope protein gp120 is toxic to human brain-cell cultures through induction of interleukin 6 and tumor necrosis factor-α. AIDS 1995;9:137-43.
21. 21. Rajora N, Boccoli G, Burns D, et al. α-MSH modulates local and circulating TNF α in experimental brain inflammation. J Neurosci 1997;17:2181-6.
22. 22. Sundar SK, Cierpial MA, Kamaraju LS, et al. Human immunodeficiency virus glycoprotein (gp120) infused into rat brain induces interleukin 1 to elevate pituitary-adrenal activity and decreases peripheral cellular immune responses. Proc Natl Acad Sci USA 1991;88:11246-50.
23. 23. Sundar SK, Becker KJ, Cierpial MA, et al. Intracerebroventricular infusion of interleukin 1 rapidly decreases peripheral cellular immune responses. Proc Natl Acad Sci USA 1989;86:6398-402.
24. 24. Catania A, Rajora N, Capsoni F, et al. The neuropeptide α-MSH has specific receptors on neutrophils and reduces chemotaxis in vitro. Peptides 1996;17:675-9.
25. 25. Dinarello CA, Thompson RC. Blocking IL-1 : interleukin 1 receptor antagonist in vivo and in vitro. Immunol Today 1991;12:405-10.
26. 26. Bazzoni F, Beutler B. The tumor necrosis factor ligand and receptor families. N Engl J Med 1996;334:1717-25.